Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Статус неизвестен Россия

12211

Observational Cohort Prospective Study of Diagnostics of Coronavirus Disease 2019 Cardiovascular Complications Using Remote Electrocardiogram Monitoring and Pulse Wave

Номер протокола12211
ФазаФаза не указана
Участников по плану — во всех странах исследования100
Сроки02.06.2022 — 30.11.2025
Начало: 2 июня 2022Окончание: 30 ноября 2025
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT05608603/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Статус исследования в реестре не указан — уточняйте в центре.
  • Возраст участников: 18–80 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 100 чел. во всех странах исследования.
  • Центров в реестре: 1 в одном городе. Список — ниже на странице.
  • Плановая дата окончания (11.2025) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст18–80 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 13 · невключение: 6

Критерии включения

  • Written informed consent to participate in the study;
  • Age 18 and over;
  • Male and female;
  • COVID-19 infection confirmed by laboratory tests (polymerase chain reaction testing, enzyme-linked immunosorbent assay (positive result at least 1 time) with a CT degree more that 25% of lung lesion.
  • No more than 3 months after discharge from infectious department
  • Non-inclusion criteria:
  • Unable to sign informed consent;
  • Mental illness (severe dementia, schizophrenia, severe depression, manic-depressive psychosis);
  • Acute coronary syndrome, acute cerebrovascular accident, pulmonary embolism within the last 3 months;
  • Oncology;
  • Diseases and conditions that can change the ECG picture and complicate the analysis of the ECG (conduction disturbance, pacemaker);
  • Inability to use a heart monitor (congenital developmental anomalies, traumatic amputation of the upper limbs, essential tremor, Parkinson's disease);
  • Severe comorbidities with life expectancy less than 1 year.

Критерии невключения

  • Refusal to further participation in the study;
  • Acute infectious diseases, tuberculosis
  • Oncology arising in the process of the study
  • Acute coronary syndrome, acute cerebrovascular accident, pulmonary embolism arising in the process of the study
  • Acute psychotic reactions arising in the process of the study;
  • Inability to use a heart monitor arising in the process of the study

Источник: ClinicalTrials.gov, NCT05608603 · запись обновлена в реестре 20 марта 2024.

Дизайн и результаты

ДизайнНаблюдательное
Участников по плану (все страны)100
Результатыбудут после окончания
Что измеряют — первичные конечные точки (10)
  • Changes in endothelin-1 in dynamics (compared with initial indicators) — In 9 months after the recovery from COVID-19
  • Changes in the diastolic function of the right and left ventricles (compared with initial indicators) — In 9 months after the recovery from COVID-19
  • Change in ejection fraction (compared with initial indicators) — In 9 months after the recovery from COVID-19
  • Changes in the volumes of the heart cavities (compared with initial indicators) — In 9 months after the recovery from COVID-19
  • Change in speed indicators on the heart valves (compared with initial indicators) — In 9 months after the recovery from COVID-19
  • Change in mean and diastolic pressure of the pulmonary artery (compared with initial indicators) — In 9 months after the recovery from COVID-19
  • Changes in the cardio-ankle vascular index and ankle-brachial index (compared with initial indicators) — In 9 months after the recovery from COVID-19
  • Changes in the spectrum of volatile organic compounds in exhaled air in patients after COVID-19 infection over time (compared with initial indicators) — In 9 months after the recovery from COVID-19
  • Change in oxygen pulse (VO2/HR) at the peak of the load — In 9 months after the recovery from COVID-19
  • Changes in ventilation parameters (tidal volume (Vt), minute ventilation (VE), Vt/FVC index (ratio of tidal volume to forced vital capacity), respiratory reserve (BR)) over time — In 9 months after the recovery from COVID-19

Цель исследования

Aim of this prospective, observational, multi-centered, randomized study is to detect cardiovascular complications in patients after coronavirus infection.

The study will include 100 patients who underwent confirmed by laboratory tests COVID-19 infection (polymerase chain reaction (PCR) testing, enzyme-linked immunosorbent assay (positive result at least 1 time)) 1-3 months ago with the degree of lung lesion more than 25%, who were admitted to the University Clinical Hospital No. 4 of I.M. Sechenov First Moscow State Medical University.

The study consists of 4 periods:

1. Screening for up to 6 months.
2. Inclusion in the study, undergoing of identical laboratory and instrumental testing.
3. Re-examination of patients. After 6 months from the initial examination (9 months after discharge from the infectious diseases department), patients will be re-examined.

4 Determination of end points, statistical data processing.

Estimated result of the study is to confirm or refute the hypothesis:

1. As a result of the analysis of ECG and pulse wave data and comparison with echocardiography data, identify cardiovascular complications of COVID-19 infection.
2. To determine the diagnostic significance of pulse wave parameters for assessing cardiovascular complications in patients with a history of COVID-19 infection (sensitivity, specificity, positive and negative predictive value).
3. Identify correlations between pulse wave parameters and biochemical markers of endothelial dysfunction (endothelin-1).
4. As a result of the analysis of exhaled air by the proton mass spectrometry, to identify markers of cardiovascular complications in patients after COVID-19 infection.
5. As a result of a cardiorespiratory stress test, determine the respiratory and cardiovascular causes of dyspnea, exercise tolerance of patients after infection with COVID-19.

Где проходит

1 центр в 1 городе

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT05608603 Официальный реестр (США) · загружено 9 ноября 2026
    Номер протокола, название, цель, сроки, число участников, спонсор, центры

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.